In the mouse, IL-6 mainly induce the differentiation of naive CD4-positive T cells into Th17 cells, whereas anti-IL-6 therapy effectively suppresses the onset of experimental autoimmune encephalomyelitis via the inhibition of the development of autoantigen-specific Th17 cells. The gene discussed is CD4; the disease is experimental autoimmune encephalomyelitis.